PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the ...
Aldeyra Therapeutics Inc.’s (NASDAQ:ALDX) Phase 3 dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution achieves the primary endpoint. Reproxalap, an investigational new drug ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat ...
DEXTENZA was observed to have a favorable safety profile and be generally well-tolerated in the allergic conjunctivitis as well as the ocular inflammation and pain clinical populations. The most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results